Countries like Germany, France, and Canada temporarily stopped using AstraZeneca's vaccine after reports of rare blood clots. There is no evidence to restrict the use of the shot, Europe's regulator says.
- The benefits of
AstraZeneca's COVID-19 vaccineoutweighs its risks, the European Medicines Agency said.
- "There is no evidence to restrict the use of the vaccine in any population," it said Wednesday.
- The EMA's investigation into reports of rare side effects it ongoing and will conclude next week.
The European regulator said on Wednesday that there was "no evidence" to restrict the use of the COVID-19 vaccine made by AstraZeneca and Oxford University in "any population."
Countries including Canada, Germany, France, and Italy have put the shot on hold for younger people as a precaution while regulators investigate reports of unusual blood clots, particularly in younger women."The benefits of the AstraZeneca vaccine in preventing COVID-19, with its associated risk of hospitalization and death, outweigh the risks of side effects," the European Medicines Agency said in a press briefing Wednesday. It's a view that's consistent with what the regulator has said in recent weeks.
Emer Cooke, EMA's executive director, said that a "causal link" between rare blood disorders and AstraZeneca's vaccine was not proven, but it was "possible" and analysis was ongoing.The EMA will aim to reach a "scientific conclusion next week," she said.
Cooke said that the EMA provides information that countries need to make decisions about vaccine rollouts, but national vaccine campaigns differ according to need - the number of infections, vaccine availability and pressure on hospitals, for example.Read more: COVID-19 Vaccine Tracker: AstraZeneca's shot proves safe and effective and is headed to the FDA
Determining whether there's a link between blood clots and AstraZeneca's shotThere had been 62 cases worldwide of a rare blood clot in the brain, reported to the EMA and 9.2 million people had been vaccinated with AstraZeneca's shot as of March 22, which amounted to 1 case in 100,000, the regulator said.
The EMA said that the blood clot in the brain called central venous sinus thrombosis (CVST) were reported mostly in women under 60 years old. But it was difficult to "disentangle" whether the vaccine was causing the clots or not. CVST can occur without the presence of vaccines. It's more likely to occur to women aged between 30 to 45, and it's more likely to occur in women than men, the agency said.
The regulator also acknowledged that the relatively high number of young women who reported CVST could be related to the vaccine's rollout - young
The EMA said that it at looked at these theories but they weren't proven.
- India records highest single-day rise of 2,61,500 COVID-19 cases and 1,501 deaths
- Odisha halts COVID-19 vaccination drive in 1,035 sites due to its acute shortage
- All Migrant workers coming to Uttar Pradesh to be quarantined
- Microsoft Remote Desktop for macOS updated with M1 chip support
- GoaMiles, a new state-backed cab aggregator service in tourists' hub has the taxi drivers on strike for 10 days